Stock Track | Novo Nordisk Soars 6.56% Intraday as UK Approves Higher Wegovy Dose for Obesity

Stock Track01-17

Novo Nordisk's (NVO) stock surged 6.56% during Friday's intraday trading session, buoyed by regulatory approval for a higher dose of its blockbuster weight-loss drug, Wegovy.

The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) approved a maximum weekly dose of 7.2 mg of Wegovy, up from the previous 2.4 mg limit. The higher dose, administered as three separate injections, is expected to enhance weight-loss efficacy for patients with obesity (BMI ≥30). This approval strengthens Novo's competitive edge in the rapidly expanding weight-loss market, where it faces rivalry from Eli Lilly's tirzepatide.

Analysts at Berenberg Bank project Wegovy's newly launched pill form could generate $1 billion in sales this year, potentially offsetting headwinds like U.S. price cuts. The firm reiterated its Buy rating and raised Novo's price target to DKK 415, citing upside to consensus estimates.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111110137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-17 00:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111110137","market":"nz","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Soars 6.56% Intraday as UK Approves Higher Wegovy Dose for Obesity","media":"Stock Track","content":"<p>Novo Nordisk's (NVO) stock surged 6.56% during Friday's intraday trading session, buoyed by regulatory approval for a higher dose of its blockbuster weight-loss drug, Wegovy.</p><p>The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) approved a maximum weekly dose of 7.2 mg of Wegovy, up from the previous 2.4 mg limit. The higher dose, administered as three separate injections, is expected to enhance weight-loss efficacy for patients with obesity (BMI ≥30). This approval strengthens Novo's competitive edge in the rapidly expanding weight-loss market, where it faces rivalry from Eli Lilly's tirzepatide.</p><p>Analysts at Berenberg Bank project Wegovy's newly launched pill form could generate $1 billion in sales this year, potentially offsetting headwinds like U.S. price cuts. The firm reiterated its Buy rating and raised Novo's price target to DKK 415, citing upside to consensus estimates.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Soars 6.56% Intraday as UK Approves Higher Wegovy Dose for Obesity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Soars 6.56% Intraday as UK Approves Higher Wegovy Dose for Obesity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-17 00:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novo Nordisk's (NVO) stock surged 6.56% during Friday's intraday trading session, buoyed by regulatory approval for a higher dose of its blockbuster weight-loss drug, Wegovy.</p><p>The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) approved a maximum weekly dose of 7.2 mg of Wegovy, up from the previous 2.4 mg limit. The higher dose, administered as three separate injections, is expected to enhance weight-loss efficacy for patients with obesity (BMI ≥30). This approval strengthens Novo's competitive edge in the rapidly expanding weight-loss market, where it faces rivalry from Eli Lilly's tirzepatide.</p><p>Analysts at Berenberg Bank project Wegovy's newly launched pill form could generate $1 billion in sales this year, potentially offsetting headwinds like U.S. price cuts. The firm reiterated its Buy rating and raised Novo's price target to DKK 415, citing upside to consensus estimates.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1111110137","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111110137","pubTimestamp":1768579980,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo Nordisk's (NVO) stock surged 6.56% during Friday's intraday trading session, buoyed by regulatory approval for a higher dose of its blockbuster weight-loss drug, Wegovy.The UK's Medicines and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"个股追踪|诺和诺德盘中大涨6.56%因英国批准更高Wegovy剂量治疗肥胖","themeId":"d806896b6091b132ff78b81fa73d2804","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk's (NVO) stock surged 6.56% during Friday's intraday trading session, buoyed by regulatory approval for a higher dose of its blockbuster weight-loss drug, Wegovy.The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) approved a maximum weekly dose of 7.2 mg of Wegovy, up from the previous 2.4 mg limit. The higher dose, administered as three separate injections, is expected to enhance weight-loss efficacy for patients with obesity (BMI ≥30). This approval strengthens Novo's competitive edge in the rapidly expanding weight-loss market, where it faces rivalry from Eli Lilly's tirzepatide.Analysts at Berenberg Bank project Wegovy's newly launched pill form could generate $1 billion in sales this year, potentially offsetting headwinds like U.S. price cuts. The firm reiterated its Buy rating and raised Novo's price target to DKK 415, citing upside to consensus estimates.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111110137","isCrawlerRequest":true}